DU Bao-min, Lu Zong-liang, Chen Zuo, Wu Yang-feng
Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Oct;34(10):890-4.
To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in coronary heart disease (CHD) patients with or without hypertension.
In this random, double-blinded, placebo controlled clinical trial, 2704 patients with hypertension and 2166 patients without hypertension were enrolled and capsule Xuezhikang 0.6 g Bid or placebo on the top of conventional therapy without other lipid-lowering drugs. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and total mortality.
Compared to placebo group, the incidence of cardiac events was reduced by 44.0% (P<0.0001) and 47.4% (P<0.0001) respectively in CHD patients with or without hypertension, and the total mortality was lowered by 35.8% (P=0.0012) and 28.6% (P=0.0737) respectively in CHD patients with or without hypertension. There was no significant difference in side effects between study groups.
Xuezhikang can reduce the cardiac events and mortality in CHD patients with or without hypertension.
评估血脂康降脂治疗能否降低伴有或不伴有高血压的冠心病（CHD）患者发生心脏事件及全因死亡的风险。
在这项随机、双盲、安慰剂对照的临床试验中，纳入了2704例高血压患者和2166例非高血压患者，在常规治疗基础上不使用其他降脂药物，给予血脂康胶囊0.6 g每日两次或安慰剂。平均随访期为4年。主要终点为非致死性心肌梗死和全因死亡。
与安慰剂组相比，伴有或不伴有高血压的冠心病患者心脏事件发生率分别降低了44.0%（P<0.0001）和47.4%（P<0.0001），伴有或不伴有高血压的冠心病患者全因死亡率分别降低了35.8%（P=0.0012）和28.6%（P=0.0737）。研究组之间副作用无显著差异。
血脂康可降低伴有或不伴有高血压的冠心病患者的心脏事件及死亡率。
Zotero 插件